Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.80 |
| ▸ | KIT | P10721 | 10/20 | 0.80 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.80 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.80 |
| ▸ | KDR | P35968 | 9/20 | 0.74 |
| ▸ | LCK | P06239 | 6/20 | 0.74 |
| ▸ | LYN | P07948 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944572 | 0.92 | MAPK14 (0.84) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2957043 | 0.92 | MAPK14 (0.84) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2946770 | 0.91 | MAPK14 (0.83) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2954260 | 0.91 | MAPK14 (0.71) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2954400 | 0.90 | MAPK14 (0.70) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2951786 | 0.89 | MAPK14 (0.80) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2953214 | 0.89 | MAPK14 (1.00) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2944492 | 0.89 | MAPK14 (0.76) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2948355 | 0.89 | MAPK14 (0.76) | MAPK14KITMAPK9MAPK10KDR | |
| SCHEMBL2955214 | 0.88 | MAPK14 (0.77) | MAPK14KITMAPK9MAPK10KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856058-B1 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-09-03 | — | — | EP | claimed |
| US-7759337-B2 | Phthalazine compounds and methods of use | AMGEN INC. (US) | 2010-07-20 | — | — | US | claimed |
| EP-1856058-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006094187-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-09-08 | — | — | WO | claimed |
| EP-1842923-B1 | Methanesulfonylaminoindole derivatives and labeled oligonucleotide probes containing them | ROCHE DIAGNOSTICS GMBH (DE) | 2015-07-15 | — | — | EP | disclosed |
| US-7759470-B2 | Labeling reagent | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1842923-A1 | Methanesulfonylaminoindole derivatives and labeled oligonucleotide probes containing them. | Roche Diagnostics GmbH (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070196852-A1 | Labeling reagent | ROCHE DIAGNOSTICS GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196852-A1 | Labeling reagent | INMT, RNGTT, DUT | MAPK14 3994/4885KIT 1670/4885MAPK9 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.